Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
February 12, 2020 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it is distributing approximately...
Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million
February 10, 2020 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on...
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
January 14, 2020 07:00 ET
|
Mereo BioPharma Group plc
Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching...
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
January 13, 2020 07:00 ET
|
Mereo BioPharma Group plc
Oncologie receives exclusive global license to develop and commercialize navicixizumab LONDON, and REDWOOD CITY, Calif., and BOSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc...
Mereo BioPharma’s Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
November 11, 2019 06:30 ET
|
Mereo BioPharma Group plc
Dose-Dependent and Statistically Significant Improvement in Areal Bone Mineral Density (BMD) Over Baseline at the Lumbar Spine, as Measured by DXA, Reaching 8.8% at 12 Months in Highest Dose Cohort...
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
October 07, 2019 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company" or the "Group," a clinical stage biopharmaceutical...
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
September 17, 2019 07:00 ET
|
Mereo BioPharma Group plc
12-Month Topline Results from Phase 2b ASTEROID Study with Setrusumab for Osteogenesis Imperfecta (OI) Expected in Q4 2019; Positive 6-Month Data to be Featured in Late-Breaking Oral Presentation at...
Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
September 10, 2019 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical...
Mereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting
September 04, 2019 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage...
Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
July 16, 2019 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today...